Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Antibiotics drive microbial imbalance and vitiligo development in mice.

Dellacecca ER, Cosgrove C, Mukhatayev Z, Akhtar S, Engelhard VH, Rademaker AW, Knight K, Le Poole IC.

J Invest Dermatol. 2019 Aug 28. pii: S0022-202X(19)33153-7. doi: 10.1016/j.jid.2019.08.435. [Epub ahead of print]

PMID:
31472106
2.

The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.

Leick KM, Rodriguez AB, Melssen MM, Benamar M, Lindsay RS, Eki R, Du KP, Parlak M, Abbas T, Engelhard VH, Slingluff CL Jr.

Ann Surg. 2019 Oct;270(4):712-722. doi: 10.1097/SLA.0000000000003522.

PMID:
31425296
3.

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, Bosenberg MW, Engelhard VH, Slingluff CL Jr.

Cancer Immunol Immunother. 2019 Jul;68(7):1121-1132. doi: 10.1007/s00262-019-02345-5. Epub 2019 May 27.

PMID:
31134297
4.

The Antigen Processing and Presentation Machinery in Lymphatic Endothelial Cells.

Santambrogio L, Berendam SJ, Engelhard VH.

Front Immunol. 2019 May 7;10:1033. doi: 10.3389/fimmu.2019.01033. eCollection 2019. Review.

5.

Comparative Transcriptomic Analysis Identifies a Range of Immunologically Related Functional Elaborations of Lymph Node Associated Lymphatic and Blood Endothelial Cells.

Berendam SJ, Koeppel AF, Godfrey NR, Rouhani SJ, Woods AN, Rodriguez AB, Peske JD, Cummings KL, Turner SD, Engelhard VH.

Front Immunol. 2019 Apr 16;10:816. doi: 10.3389/fimmu.2019.00816. eCollection 2019.

6.

Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma.

Melssen MM, Olson W, Wages NA, Capaldo BJ, Mauldin IS, Mahmutovic A, Hutchison C, Melief CJM, Bullock TN, Engelhard VH, Slingluff CL Jr.

Oncoimmunology. 2018 Aug 6;7(10):e1490855. doi: 10.1080/2162402X.2018.1490855. eCollection 2018.

7.

Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.

Rodriguez AB, Peske JD, Engelhard VH.

Methods Mol Biol. 2018;1845:241-257. doi: 10.1007/978-1-4939-8709-2_14.

8.

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW.

J Clin Invest. 2018 Apr 2;128(4):1338-1354. doi: 10.1172/JCI93303. Epub 2018 Feb 26.

9.

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr.

J Immunol. 2018 Jan 15;200(2):432-442. doi: 10.4049/jimmunol.1701269. Review.

10.

Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry.

Woods AN, Wilson AL, Srivinisan N, Zeng J, Dutta AB, Peske JD, Tewalt EF, Gregg RK, Ferguson AR, Engelhard VH.

Cancer Immunol Res. 2017 Dec;5(12):1062-1073. doi: 10.1158/2326-6066.CIR-17-0190. Epub 2017 Nov 2.

11.

The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.

Mohammed F, Stones DH, Zarling AL, Willcox CR, Shabanowitz J, Cummings KL, Hunt DF, Cobbold M, Engelhard VH, Willcox BE.

Oncotarget. 2017 Apr 8;8(33):54160-54172. doi: 10.18632/oncotarget.16952. eCollection 2017 Aug 15.

12.

Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma.

Malaker SA, Ferracane MJ, Depontieu FR, Zarling AL, Shabanowitz J, Bai DL, Topalian SL, Engelhard VH, Hunt DF.

J Proteome Res. 2017 Jan 6;16(1):228-237. doi: 10.1021/acs.jproteome.6b00496. Epub 2016 Sep 13.

13.

Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.

Peske JD, Woods AB, Engelhard VH.

Adv Cancer Res. 2015;128:263-307. doi: 10.1016/bs.acr.2015.05.001. Epub 2015 Jun 1. Review.

14.

Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity.

Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH.

Nat Commun. 2015 May 13;6:7114. doi: 10.1038/ncomms8114.

15.

Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction.

Rouhani SJ, Eccles JD, Riccardi P, Peske JD, Tewalt EF, Cohen JN, Liblau R, Mäkinen T, Engelhard VH.

Nat Commun. 2015 Apr 10;6:6771. doi: 10.1038/ncomms7771.

16.

Regulation of T-cell Tolerance by Lymphatic Endothelial Cells.

Rouhani SJ, Eccles JD, Tewalt EF, Engelhard VH.

J Clin Cell Immunol. 2014;5. pii: 1000242.

17.

MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.

Zarling AL, Obeng RC, Desch AN, Pinczewski J, Cummings KL, Deacon DH, Conaway M, Slingluff CL Jr, Engelhard VH.

Cancer Res. 2014 Dec 1;74(23):6784-95. doi: 10.1158/0008-5472.CAN-14-0043. Epub 2014 Oct 8.

18.

Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Longley BJ, Engelhard VH, Mehrotra S, Le Poole IC.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1075-85. doi: 10.1111/pcmr.12284. Epub 2014 Jul 21.

19.

Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment.

Cohen JN, Tewalt EF, Rouhani SJ, Buonomo EL, Bruce AN, Xu X, Bekiranov S, Fu YX, Engelhard VH.

PLoS One. 2014 Feb 4;9(2):e87740. doi: 10.1371/journal.pone.0087740. eCollection 2014.

20.

Regulatory T cells and vasectomy.

Rival C, Wheeler K, Jeffrey S, Qiao H, Luu B, Tewalt EF, Engelhard VH, Tardif S, Hardy D, del Rio R, Teuscher C, Tung K.

J Reprod Immunol. 2013 Nov;100(1):66-75. doi: 10.1016/j.jri.2013.08.004. Epub 2013 Sep 8.

21.

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

Cobbold M, De La Peña H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, Craddock C, Williams ME, Hunt DF, Engelhard VH.

Sci Transl Med. 2013 Sep 18;5(203):203ra125. doi: 10.1126/scitranslmed.3006061.

22.

Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues.

Brinkman CC, Peske JD, Engelhard VH.

Front Immunol. 2013 Aug 19;4:241. doi: 10.3389/fimmu.2013.00241. eCollection 2013.

23.

Peripheral tissue homing receptors enable T cell entry into lymph nodes and affect the anatomical distribution of memory cells.

Brinkman CC, Rouhani SJ, Srinivasan N, Engelhard VH.

J Immunol. 2013 Sep 1;191(5):2412-25. doi: 10.4049/jimmunol.1300651. Epub 2013 Aug 7. Erratum in: J Immunol. 2013 Dec 15;191(12):6292. J Immunol. 2014 Apr 15;192(8):3992-5.

24.

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H.

Cancer Cell. 2013 Apr 15;23(4):516-26. doi: 10.1016/j.ccr.2013.03.018.

25.

Lymphatic endothelial cells - key players in regulation of tolerance and immunity.

Tewalt EF, Cohen JN, Rouhani SJ, Engelhard VH.

Front Immunol. 2012 Sep 28;3:305. doi: 10.3389/fimmu.2012.00305. eCollection 2012.

26.

Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.

Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP, Conaway MR, Bender TP, Tung KS, Vella AT, Adler AJ, Chen L, Engelhard VH.

Blood. 2012 Dec 6;120(24):4772-82. doi: 10.1182/blood-2012-04-427013. Epub 2012 Sep 19.

27.

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.

Thompson ED, Enriquez HL, Fu YX, Engelhard VH.

J Exp Med. 2010 Aug 2;207(8):1791-804. doi: 10.1084/jem.20092454. Epub 2010 Jul 26.

28.

Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.

Li Y, Depontieu FR, Sidney J, Salay TM, Engelhard VH, Hunt DF, Sette A, Topalian SL, Mariuzza RA.

J Mol Biol. 2010 Jun 18;399(4):596-603. doi: 10.1016/j.jmb.2010.04.037. Epub 2010 Apr 24.

29.

Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation.

Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, Ruddell A, Farr AG, Tung KS, Engelhard VH.

J Exp Med. 2010 Apr 12;207(4):681-8. doi: 10.1084/jem.20092465. Epub 2010 Mar 22.

30.

CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors.

Ferguson AR, Engelhard VH.

J Immunol. 2010 Apr 15;184(8):4079-86. doi: 10.4049/jimmunol.0901903. Epub 2010 Mar 8.

31.

Targeting allergen to FcgammaRI reveals a novel T(H)2 regulatory pathway linked to thymic stromal lymphopoietin receptor.

Hulse KE, Reefer AJ, Engelhard VH, Patrie JT, Ziegler SF, Chapman MD, Woodfolk JA.

J Allergy Clin Immunol. 2010 Jan;125(1):247-56.e1-8. doi: 10.1016/j.jaci.2009.10.027.

32.

Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Gregg RK, Nichols L, Chen Y, Lu B, Engelhard VH.

J Immunol. 2010 Feb 15;184(4):1909-17. doi: 10.4049/jimmunol.0902778. Epub 2010 Jan 18.

33.

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.

Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12073-8. doi: 10.1073/pnas.0903852106. Epub 2009 Jul 6.

34.

N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase.

Ostankovitch M, Altrich-Vanlith M, Robila V, Engelhard VH.

J Immunol. 2009 Apr 15;182(8):4830-5. doi: 10.4049/jimmunol.0802902.

35.

Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Nicholls S, Piper KP, Mohammed F, Dafforn TR, Tenzer S, Salim M, Mahendra P, Craddock C, van Endert P, Schild H, Cobbold M, Engelhard VH, Moss PA, Willcox BE.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3889-94. doi: 10.1073/pnas.0900411106. Epub 2009 Feb 20.

36.

MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes.

Robila V, Ostankovitch M, Altrich-Vanlith ML, Theos AC, Drover S, Marks MS, Restifo N, Engelhard VH.

J Immunol. 2008 Dec 1;181(11):7843-52.

37.

Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.

Mohammed F, Cobbold M, Zarling AL, Salim M, Barrett-Wilt GA, Shabanowitz J, Hunt DF, Engelhard VH, Willcox BE.

Nat Immunol. 2008 Nov;9(11):1236-43. doi: 10.1038/ni.1660. Epub 2008 Oct 5.

38.

Activated CD8 T cells redistribute to antigen-free lymph nodes and exhibit effector and memory characteristics.

Brinkman CC, Sheasley-O'Neill SL, Ferguson AR, Engelhard VH.

J Immunol. 2008 Aug 1;181(3):1814-24.

39.

Strategies and challenges in eliciting immunity to melanoma.

Ferguson AR, Nichols LA, Zarling AL, Thompson ED, Brinkman CC, Hargadon KM, Bullock TN, Engelhard VH.

Immunol Rev. 2008 Apr;222:28-42. doi: 10.1111/j.1600-065X.2008.00620.x.

40.
41.

Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases.

Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prévost-Blondel A.

J Immunol. 2008 Jan 1;180(1):130-7.

42.

Targeting Fel d 1 to FcgammaRI induces a novel variation of the T(H)2 response in subjects with cat allergy.

Hulse KE, Reefer AJ, Engelhard VH, Satinover SM, Patrie JT, Chapman MD, Woodfolk JA.

J Allergy Clin Immunol. 2008 Mar;121(3):756-762.e4. Epub 2007 Dec 20.

PMID:
18086491
43.

Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263.

Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH.

J Immunol. 2007 Sep 1;179(5):2669-71. No abstract available.

44.
45.

NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury.

Li L, Huang L, Sung SS, Lobo PI, Brown MG, Gregg RK, Engelhard VH, Okusa MD.

J Immunol. 2007 May 1;178(9):5899-911.

46.

Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells.

Sheasley-O'Neill SL, Brinkman CC, Ferguson AR, Dispenza MC, Engelhard VH.

J Immunol. 2007 Feb 1;178(3):1512-22.

47.

Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation.

Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J.

J Exp Med. 2006 Nov 27;203(12):2639-48. Epub 2006 Nov 6.

48.

Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes.

Hargadon KM, Brinkman CC, Sheasley-O'neill SL, Nichols LA, Bullock TN, Engelhard VH.

J Immunol. 2006 Nov 1;177(9):6081-90.

49.

Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases.

Altrich-VanLith ML, Ostankovitch M, Polefrone JM, Mosse CA, Shabanowitz J, Hunt DF, Engelhard VH.

J Immunol. 2006 Oct 15;177(8):5440-50.

50.

Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.

Zarling AL, Polefrone JM, Evans AM, Mikesh LM, Shabanowitz J, Lewis ST, Engelhard VH, Hunt DF.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14889-94. Epub 2006 Sep 25.

Supplemental Content

Loading ...
Support Center